Biocept Announces Participation in MultiPlan's Networks
More than 99 million healthcare consumers now have access to Biocept's suite of blood-based diagnostics through healthcare payors and plans
"Our ability to gain agreements with companies such as
"We are excited about becoming a participating provider with
About
Founded in 1980,
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which they
are based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect," "anticipate,"
"estimate," "believe," "intend," or "project" or the negative of these
words or other variations on these words or comparable terminology. To
the extent that statements in this release are not strictly historical,
including without limitation statements as to the use of our liquid
biopsy assays by physicians, the use of liquid biopsy generally, and the
impact of liquid biopsy on diagnostic strategies and healthcare costs,
such statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to numerous
risk factors as set forth in our
View source version on businesswire.com: http://www.businesswire.com/news/home/20150928005309/en/
Investors:
LHA
jcain@lhai.com
Source:
News Provided by Acquire Media